血压与缺血性心肌病患者长期结局的关联:STICH试验分析
基于STICH试验1212例射血分数≤35%且适合CABG的冠心病患者,中位随访9.8年,分析血压与死亡结局的关系。结果显示收缩压与死亡率呈U型关系,5年标志分析最显著(P=0.002),最有利的收缩压范围为120-130 mmHg,舒张压为75-85 mmHg。
要点
- 缺血性心肌病患者收缩压与长期死亡率呈U型关系,5年时最显著
- 最有利的收缩压范围为120-130 mmHg,舒张压为75-85 mmHg
- 高血压病史和基线血压对长期死亡率无显著影响,与治疗方式无交互
核心结论
- 缺血性心力衰竭患者血压与死亡率呈强U型关系,提示最佳收缩压可能在120-130 mmHg之间。
- 低血压是预后不良的标志,可能需要其他干预策略。
研究设计与样本
- STICH试验的事后分析,纳入1212例射血分数≤35%且冠心病适合CABG的患者,随机接受CABG或单纯药物治疗。
- 中位随访9.8年,采用标志分析从随机后1、2、3、4、5年开始,将既往收缩压平均值与后续死亡率关联。
主要发现
- 高血压病史和基线血压对长期死亡率无显著影响,与药物或CABG治疗无显著交互作用。
- 标志分析显示收缩压与死亡率呈渐进性U型关系,5年标志分析最强(χ2=14.52,P=0.002)。
- 舒张压与结局的关系类似,最有利的收缩压范围为120-130 mmHg,舒张压为75-85 mmHg。
- 较低和较高的血压均与更差的结局相关,组间降压药物无差异。
关键数值与推荐
- 标志分析1、2、3、4、5年的χ2和P值分别为:7.08,P=0.069;8.72,P=0.033;9.86,P=0.020;8.31,P=0.040;14.52,P=0.002。
- 最有利的收缩压范围为120-130 mmHg,舒张压为75-85 mmHg。
临床怎么用
- 对于缺血性心肌病伴左室功能不全患者,收缩压维持在120-130 mmHg可能获益。
- 低血压应视为预后不良的标志,需关注并考虑其他干预策略。
- 高血压病史不影响长期死亡率,但高血压可能需药物干预。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Hypertension (HTN) is a well-known contributor to cardiovascular disease, including heart failure (HF) and coronary artery disease, and is the leading risk factor for premature death world-wide. A J- or U-shaped relationship has been suggested between blood pressure (BP) and clinical outcomes in different studies. However, there is little information about the significance of BP on the outcomes of patients with coronary artery disease and left ventricular dysfunction. This study aimed to determine the relationship between BP and mortality outcomes in patients with ischaemic cardiomyopathy. METHODS AND RESULTS: The influence of BP during a median follow-up of 9.8 years was studied in a total of 1212 patients with ejection fraction ≤35% and coronary disease amenable to coronary artery bypass grafting (CABG) who were randomized to CABG or medical therapy alone (MED) in the STICH (Surgical Treatment for Ischaemic Heart Failure) trial. Landmark analyses were performed starting at 1, 2, 3, 4, and 5 years after randomization, in which previous systolic BP values were averaged and related to subsequent mortality through the end of follow-up with a median of 9.8 years. Neither a previous history of HTN nor baseline BP had any significant influence on long-term mortality outcomes, nor did they have a significant interaction with MED or CABG treatment. The landmark analyses showed a progressive U-shaped relationship that became strongest at 5 years (χ2 and P-values: 7.08, P = 0.069; 8.72, P = 0.033; 9.86; P = 0.020; 8.31, P = 0.040; 14.52, P = 0.002; at 1, 2, 3, 4, and 5-year landmark analyses, respectively). The relationship between diastolic BP (DBP) and outcomes was similar. The most favourable outcomes were observed in the SBP range 120-130, and DBP 75-85 mmHg, whereas lower and higher BP were associated with worse outcomes. There were no differences in BP-lowering medications between groups. CONCLUSION: A strong U-shaped relationship between BP and mortality outcomes was evident in ischaemic HF patients. The results imply that the optimal SBP might be in the range 120-130 mmHg after intervention, and possibly be subject to pharmacologic action regarding high BP. Further, low BP was a marker of poor outcomes that might require other interactions and treatment strategies. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00023595.
引用
- Andersson B, She L, Tan RS, et al. The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial. Eur Heart J. 2018. PMID: 30113633. doi:10.1093/eurheartj/ehy438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。